Vimarsana
Biggest News Aggregation in the World

Page 4 - Dan Forche News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dan Forche. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dan Forche Today - Breaking & Trending Today

PreludeDx™ to Present DCISionRTÒ and Novel Residual Risk Subtype Prospective Data During Scientific Oral Session at ASTRO 2022 Annual Meeting - Vimarsana News

PreludeDx™ to Present DCISionRTÒ and Novel Residual Risk Subtype Prospective Data During Scientific Oral Session at ASTRO 2022 Annual Meeting

Published: October 21, 2022

/PRNewswire/ -- Prelude Corporation (PreludeDxä), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today that...

Source: prnewswire.com
Related Topics:
San AntonioUnited StatesWestern AustraliaChirags ShahDan ForcheAndrew WadeCory DunnYvonne Zissiadis JrPrnewswire Prelude Corporation PreludedxNational Cancer InstitutePrelude CorporationAmerican Society For Radiation OncologyTaussig Cancer InstituteUniversity Of California San FranciscoDepartment Of Radiation OncologyHenryb Gonzalez Convention CenterResidual Risk SubtypeAnnual American SocietyRadiation OncologyConvention CenterRe Thinking Clinicopathologic Risk AssessmentPooled DataValidation Studies ComparingClinicopathologic FeaturesBreast Radiation Oncology
PreludeDx™ Announces Publication of Residual Risk after Radiation Therapy Data in the International Journal of Radiation Oncology•Biology•Physics - Vimarsana News

PreludeDx™ Announces Publication of Residual Risk after Radiation Therapy Data in the International Journal of Radiation Oncology•Biology•Physics

Published: September 20, 2022

/PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced the...

Source: prnewswire.com
Related Topics:
United StatesDan ForcheAndrew WadeJuliea MargenthalerCory DunnFrank ViciniPrnewswire Prelude Corporation PreludedxNational Cancer InstituteInternational Journal Of Radiation OncologyWashington University School Of MedicinePrelude CorporationUniversity Of California San FranciscoOnly TestUnexpectedly High Residual RiskInternational JournalRadiation OncologyResidual Risk SubtypeRadiation OncologistWashington University SchoolCalifornia San FranciscoKnow Your RiskFjord VenturesDecision Score
PreludeDx Presents New Data at AACR Confirming No Significant Radiation Benefit in DCISionRT Low-risk Patients - Vimarsana News

PreludeDx Presents New Data at AACR Confirming No Significant Radiation Benefit in DCISionRT Low-risk Patients

Published: September 9, 2022

/PRNewswire/-- Prelude Corporation (PreludeDxä), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced compelling...

Source: prnewswire.com
Related Topics:
United StatesDan ForcheAndrew WadeRachel RabinovitchCory DunnNational Cancer InstitutePrelude Corporation PreludedxPrelude CorporationAmerican Association For Cancer ResearchUniversity Of ColoradoUniversity Of California San FranciscoRisk RecurrenceAmerican AssociationCancer ResearchSpecial ConferenceRadiation OncologyCalifornia San FranciscoKnow YourFjord VenturesDecision ScoreKnow Your RiskHealth Care Amp Hospitals Medical Pharmaceuticals Biotechnology
PreludeDx™ Presents New DCISionRT® Data on the Effectiveness of Endocrine Therapy in DCIS Patients at the ASCO 2022 Annual Meeting - Vimarsana News

PreludeDx™ Presents New DCISionRT® Data on the Effectiveness of Endocrine Therapy in DCIS Patients at the ASCO 2022 Annual Meeting

Published: June 7, 2022

/PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced compelling...

Source: prnewswire.com
Related Topics:
Mccormick PlaceUnited StatesPat WhitworthDan ForcheAndrew WadeCory DunnPrnewswire Prelude Corporation PreludedxNational Cancer InstituteAmerican Society Of Clinical OncologyNashville Breast CenterUniversity Of TennesseePrelude CorporationUniversity Of California San FranciscoAmerican SocietyClinical OncologyAnnual MeetingBreast Surgical Oncologist DirectorAssociate ProfessorManaging PartnerCalifornia San FranciscoKnow Your RiskFjord VenturesDecision Score
PreludeDx™ to Present DCIS Study Results Assessing Benefit of Adjuvant Endocrine Therapy Using DCISionRT® During Oral Presentation at ASCO 2022 Annual Meeting - Vimarsana News

PreludeDx™ to Present DCIS Study Results Assessing Benefit of Adjuvant Endocrine Therapy Using DCISionRT® During Oral Presentation at ASCO 2022 Annual Meeting

Published: May 24, 2022

/PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today that...

Source: prnewswire.com
Related Topics:
Mccormick PlaceUnited StatesPat WhitworthDan ForcheAndrew WadeCory DunnPrnewswire Prelude Corporation PreludedxNational Cancer InstituteAmerican Society Of Clinical OncologyNashville Breast CenterUniversity Of TennesseePrelude CorporationUniversity Of California San FranciscoAmerican SocietyClinical OncologyEndocrine TherapyAssociate ProfessorCalifornia San FranciscoDecision ScoreKnow Your RiskFjord VenturesInvestor Contact